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Abstract
Background: The antiangiogenic agent cilengitide disrupts integrin binding to the extracellular
matrix leading to apoptosis of activated endothelial cells. Integrins are also widely expressed in
malignant glioma and integrin inhibitors may directly target tumor cells in this disease. Aim of the
current study was to investigate effects of cilengitide on endothelial and glioma cells on molecular
and cellular levels.
Results: Cilengitide caused dose-dependent detachment of endothelial cells from cell culture
dishes. Proliferation of endothelial cells was significantly inhibited while the proportion of apoptotic
cells was increased. Incubation of integrin-expressing glioma cells with cilengitide caused rounding
and detachment after 24 hours as observed with endothelial cells. Cilengitide inhibited proliferation
and induced apoptosis in glioma cells with methylated MGMT promotor when given alone or in
combination with temozolomide. In endothelial as well as glioma cells cilengitide inhibited
phosphorylation of FAK, Src and Akt. Assembly of cytoskeleton and tight junctions was heavily
disturbed in both cell types.
Conclusion: Cilengitide inhibits integrin-dependent signaling, causes disassembly of cytoskeleton,
cellular detachment and induction of apoptosis in endothelial and glioma cells thereby explaining
the profound activity of integrin inhibitors in gliomas. The combination of cilengitide with
temozolomide exerted additive effects in glioma cells as observed clinically.
Background
Angiogenesis, the formation of blood vessels from pre-
existing vasculature, has been identified as an essential
mechanism in tumor growth [1]. This process is mediated
by proangiogenic growth factors such as vascular endothe-
lial growth factor (VEGF) inducing proliferation, migra-
tion and tube formation of endothelial cells [2]. Another
important feature is the interaction of endothelial cells
with surrounding extracellular matrix (ECM) that is medi-
ated by integrins. Integrins are transmembrane receptors
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composed of two subunits binding to ECM and base
membrane proteins [3]. Integrin binding mediates adhe-
sion to surrounding structures and regulates cell survival,
growth and mobility [4]. Of more than 20 known α/β het-
erodimers the integrins αvβ3 and αvβ5 are predominantly
expressed in proangiogenic endothelial cells [5,6]. A vari-
ety of blocking agents and antibodies targeting either one
or both integrins has been developed for antiangiogenic
therapy. Cilengitide, a cyclic pentapeptide mimicking the
Arg-Gly-Asp (RGD) binding site, was identified as a
potent and selective integrin antagonist [7] inhibiting
binding to ECM components of αvβ3 and αvβ5 integrins.
It was shown to inhibit VEGF and bFGF-induced migra-
tion and tube formation in vitro [8]. Cilengitide inhibits
proliferation and differentiation of endothelial progenitor
cells playing an important role in neoangiogenesis in can-
cer [9]. In preclinical models, cilengitide was synergistic
with radioimmunotherapy in breast cancer and ortho-
topic brain tumor models [10,11].
Expression of αvβ3 and αvβ5 integrins is not restricted
to activated endothelial cells. Especially brain tumors
are known to widely express these integrin family mem-
bers in tumor cells [12-14]. Labelled integrin antibodies
have been used for tumor imaging in glioma models in
vivo [15] and cilengitide as well as other inhibitors have
been successfully tested in preclinical models of glioma
[16,17]. While failing in a large trial of pancreatic can-
cer [18], cilengitide has been shown to be active in
malignant glioma given alone [19,20] or in combina-
tion with chemotherapy [21]. However, additive activ-
ity of the combination of cilengitide with
temozolomide was seen only in patients with methyl-
ated promotor of O6-methylguanine DNA methyltrans-
ferase (MGMT), so far known as a predicitve marker for
temozolomide therapy.
Direct effects of integrin inhibition on brain tumors were
suggested from antisense experiments in medulloblast-
oma cell lines where growth inhibition and induction of
apoptosis was observed [22]. In vitro, cilengitide caused
detachment of U87 and DAOY cells with consecutive
apoptosis induction depending on the matrix used [23].
However, no further data on signaling effects of cilen-
gitide either cell type have been shown so far. Therefore,
the current study was performed to investigate the mor-
phological and molecular mechanisms induced by cilen-
gitide in endothelial and in glioma cells.
Methods
Cell culture and Reagents
Human microvascular endothelial cells (HMEC-1), kind
gift from Centre for Disease Control and Prevention,
Atlanta, U.S.A., were grown in MCDB 131-medium
(Gibco) supplemented with 5% fetal bovine serum (FBS,
Gibco), 2 mM L-glutamine (Gibco), 10 ng/ml epidermal
growth factor (ICN, Costa Mesa, CA, U.S.A.) and 1 μg/ml
hydrocortisone (ICN), and maintained on uncoated
dishes in a 5% CO2/95% air atmosphere in a humidified
incubator at 37°C. Porcine aortic endothelial cells stably
transfected with KDR (PAE-KDR), provided by Shay
Soker, Winston-Salem, NC, were maintained in F-12/
HAM medium supplemented with 5% fetal bovine serum
at 37°C in 5% CO2/95% air. Commercial human umbil-
ical vein endothelial cells (HUVECs) (Lonza) were cul-
tured in EGM-2 medium (Clonetics) including 2% fetal
calf serum. The human glioblastoma cell lines G28 and
G44 [24,25], kindly provided from the Department of
Neurosurgery, University Hospital Hamburg-Eppendorf,
were cultured in Modified Eagle's Medium supplemented
with 10% fetal bovine serum on uncoated dishes. Cilen-
gitide (CGT) was kindly provided by Merck Serono,
Darmstadt, Germany. Stock solutions were diluted in ster-
ile physiological saline solution at 20 mg/ml. Cells were
incubated with cilengitide in final concentrations of 1, 5
and 50 μg/ml. Temozolomide (TMZ) was purchased from
Bristol Myers Squibb, Munich. Stock solution was diluted
in DMSO at 5 mg/ml. Cells were treated with temozolo-
mide in a final concentration of 5 μg/ml. Texas Red-X
phalloidin was from Invitrogen, mouse monoclonal anti
phospho-Akt (Ser473) antibody was from Cell Signaling,
rabbit polyclonal anti phospho-Src (Y418) antibody was
from Biosource, mouse monoclonal anti phospho-Src
(Y416) was from Biomol, mouse monoclonal anti Src
antibody was from Upstate (NY, USA), mouse mono-
clonal anti phospho-FAK (Y397) was from BD Bio-
sciences, rabbit polyclonal anti ZO-1, anti Erk1/2, mouse
monoclonal anti phospho-Erk and anti β-actin antibodies
were from Santa Cruz Biotechnology.
Tissue culture plates were incubated with a 12 mg/ml pol-
yHEMA (Poly(2-hydroxyethyl methacrylate); Sigma
Aldrich) ethanol solution at 37°C or with 10 μg/ml
fibronectin (Harbor Bio-Products, Norwood, MA, USA) at
4°C overnight when indicated.
Proliferation
HMEC-1, G28 and G44 cells (1 × 104 per well) were
seeded on uncoated 48 well plates and incubated in
serum free medium, medium containing 4% FCS or
medium containing 4% FCS with cilengitide (1, 5 and 50
μg/ml) or/and temozolomide (5 μg/ml). For experiments
with temozolomide, control cells were treated with
medium containing 4% FCS and DMSO at the equivalent
concentration used for the temozolomide stock solution.
Each stimulation was performed in triplicate. After incu-
bation for 24, 48 and 72 hours at 37°C cells were
trypsinized and counted.Journal of Experimental & Clinical Cancer Research 2008, 27:86 http://www.jeccr.com/content/27/1/86
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Apoptosis
HMEC-1, G28 and G44 cells (5 × 105) were incubated on
uncoated dishes with and without cilengitide (1, 5 and 50
μg/ml) for 24 hours at 37°C. G28 and G44 cells (2 × 105)
were incubated with temozolomide (5 μg/ml) and cilen-
gitide (5 μg/ml) in combination or separately for 48 hours
at 37°C. For experiments with temozolomide, control
cells were treated with medium containing 4% FCS and
DMSO at the equivalent concentration used for the temo-
zolomide stock solution. Apoptosis was assessed after
staining with FITC-labeled annexin-V and PI (BD
Pharmingen) by flow cytometric analysis. Positive stain-
ing with FITC-labeled annexin-V reflects a shift of phos-
phatidylserine from the inner to the outer layer of the
cytoplasmatic membrane, which occurs early in apopto-
sis. Annexin-V-positive and PI-negative cells were scored
as early apoptotic cells. Cells labeled by annexin V and PI
have been determined as late apoptotic. Annexin negative
and PI-positive events display necrotic cells.
Immunofluorescence Analysis
HMEC-1 and G28 cells were plated on cover slips and
treated with and without cilengitide (1, 5 and 50 μg/ml)
for 1 hour at 37°C. Cells were fixed with 4% paraformal-
dehyde, permeabilized with methanol, and stained for
ZO-1 (Santa Cruz Biotechnology) and actin (PE-phalloi-
din, Invitrogen). Immunofluorescence analysis was car-
ried out with an Axioplan (Zeiss) inverted microscope.
Western blotting
Protein extracts were prepared with lysis buffer solution
containing 50 mM Tris-HCl pH 7,4, 150 mM NaCl, 100
mM EGTA, 1% Nonidet P-40, 10% Na-deoxycholate, 1×
protease inhibitor cocktail (Sigma Aldrich) and 1 mM
sodium orthovanadate. Protein lysates were boiled in
SDS-sample buffer before being applied into a 10% SDS-
PAGE. After electrotransfer to nitrocellulose membranes
(Schleicher & Schuell, Dassel, Germany) and blocking in
TBS-T buffer containing 5% non-fat milk overnight, blots
were incubated with the appropriate primary antibody.
The subsequent incubation with the peroxidase-conju-
gated secondary antibodies was followed by detection
using ECL Western blotting detection reagents (Amer-
sham). Specific bands were quantified by densitometric
analysis using the GS-800 Calibrated Densitometer and
Quantity-one software (BioRad).
RNA isolation, reverse transcription and RT-PCR
Total cellular RNA from HMEC-1, G28 and G44 cells was
extracted using RNeasy Kit from Qiagen. 3 μg of total RNA
each were reverse transcribed into cDNA using the You-
Prime First-Strand cDNA synthesis kit (Amersham). Fol-
lowing primers were used to amplify the genes encoding
integrin subunits αv and β3: integrin αv (671 bp) forward
(5'-cttcaacctagacgtggacagt-3') and reverse (5'-ttgaaatctc-
cgacagccacag-3'), integrin β3 (123 bp) forward (5'-agaa-
gagccagagtgtccca-3') and reverse (5'-gaattcttttcggtcgagga-
3'). For amplification, touch down-PCR was performed
(one cycle from 65°C-55°C and 25 cycles at 55°C). The
amplification products were visualized on a 1% ethidium
bromide-stained agarose gel.
Methylation-specific PCR
DNA was extracted using QIAmp DNA Mini Kit from Qia-
gen. 2 μg genomic DNA was denaturated and chemical
modificated via bisulfite treatment using the EZ DNA
Methylation-Gold Kit from Zymo Research. For glioma
cell lines (G28 and G44) and normal lymphocytes DNA
was first amplified with flanking PCR primers as previ-
ously described [26]. The resulting fragment was used as a
template for the MSP reaction. Subsequent PCR was per-
formed with specific primers for either methylated or the
modified unmethylated promotor region of MGMT gene.
Primer sequences for the unmethlyated reaction were: 5'-
TTT GTG TTT TGA TGT TTG TAG GTT TTT GT-3' (upper
primer) and 5'-AAC TCC ACA CTC TTC CAA AAA CAA
AAC A-3' (lower primer) and for the methylated reaction
5'-TTT CGA CGT TCG TAG GTT TTC GC-3' (upper primer)
and 5'-GCA CTC TTC CGA AAA CGA AAC G-3' (lower
primer). The annealing temperature was 59°C. Universal
methylated human DNA Standard was used as a positive
control for methylated alleles of MGMT and DNA from
normal lymphocytes was used as a negative control. The
PCR products were separated on a 4% agarose gel.
Results
Effect of cilengitide on endothelial cells
We first studied the effect of cilengitide on endothelial cell
attachment in vitro. The human microvascular endothelial
cell line HMEC-1 cultured in monolayer on uncoated
dishes was incubated with and without cilengitide at con-
centrations of 1, 5 and 50 μg/ml. As shown in figure 1A,
cilengitide induced a dose dependent detachment of
HMEC-1 cells, accompanied by striking morphologic
changes after 24 hours incubation.
Cilengitide inhibits proliferation and induces apoptosis in 
endothelial cells
Cilengitide, added at concentrations of 1, 5 and 50 μg/ml
over a period of 72 hours, significantly decreased prolifer-
ation of HMEC-1 cells grown on uncoated dishes in vitro.
We observed a dose-dependent reduction of endothelial
cell counts, as shown in figure 1B. At a concentration of 1
μg/ml, cilengitide induced 33%, 59% and 44% inhibition
after 24, 48 and 72 hours, respectively. In contrast, at con-
centrations of 5 and 50 μg/ml almost no proliferation of
endothelial cells was observed comparable to the effect of
serum starvation.Journal of Experimental & Clinical Cancer Research 2008, 27:86 http://www.jeccr.com/content/27/1/86
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To investigate whether apoptosis was responsible for the
decrease of adherent endothelial cells treated with cilen-
gitide, we measured Annexin V/propidium iodide (PI)
positive cells after incubation with and without cilen-
gitide at varying concentrations. In HMEC-1 cells cilen-
gitide had a significant pro-apoptotic effect, which was
more profound with increasing concentrations (1, 5 and
50 μg/ml) after 24 hours incubation (figure 1C).
Effect of Cilengitide on glioma cells
Cilengitide has been reported to inhibit glioblastoma
growth via suppressing angiogenesis [16]. Since cilen-
gitide acts as antagonist to integrin αvβ3 and αvβ5 and
both integrins are expressed in glioma cells, especially on
the periphery of high-grade gliomas [13], we asked
whether cilengitide has a direct effect on glioma cells.
Human glioma cell lines G28 and G44 expressing
integrins αvβ3 and αvβ5 (data not shown) were incubated
with increasing concentrations of cilengitide and changes
were studied after 24 hours. Similar to endothelial cells,
cilengitide inhibited adhesion of G44 and G28 glioma
cells in a dose-dependent manner (fig. 2). In contrast to
control cell cultures, where few cells detached (fig. 2A–
2B), G28 (fig. 2C) and G44 (fig. 2D) cells treated with 1
μg/ml cilengitide for 24 hours showed striking cellular
detachment. After 24 hours exposure to 5 μg/ml (fig. 2E–
2F) and 50 μg/ml (fig. 2G–2H) cilengitide, almost all cells
were rounded up, completely detached and seemed to
form cell clusters.
Cilengitide inhibits proliferation and induces apoptosis in 
glioma cells
Glioma cell lines G28 and G44 were treated with 1, 5 and
50 μg/ml cilengitide and cell counts were determined after
24, 48 and 72 hours. We observed an inhibitory effect on
cell proliferation already at the lowest concentration (1
μg/ml) with significant differences becoming visible after
48 hours (fig. 3A–3B). Higher concentrations of cilen-
gitide abolished cell proliferation and induced apoptosis
already after 24 hours exposure to the drug. Annexin V/
propidium iodide staining revealed the presence of 18%
apoptotic G28 and 30% apoptotic G44 cells after treat-
ment with 5 μg/ml cilengitide. At a concentration of 50
μg/ml, 35% – 50% of G28 and G44 cells respectively
underwent apoptosis showing a dose dependent apopto-
sis induction in glioma cells (fig. 3C–3D).
In contrast to integrin-mediated cell death of adherent
cells, apoptosis of cells loosing adherence is termed
anoikis [27]. To compare cilengitide-induced apoptosis
with anoikis, G28 cells were seeded on polyHEMA-coated
surfaces that totally prevent cell adhesion. The rate of
apoptotic cells when G28 were cultured on polyHEMA
was identical to those observed with cilengitide treatment
Effects of cilengitide on endothelial cell proliferation and apoptosis Figure 1
Effects of cilengitide on endothelial cell proliferation and apoptosis. (A) Adhesion and morphology. HMEC-1 
endothelial cells grown on uncoated dishes were treated for 24 hours with control medium or cilengitide at concentrations of 
1 μg/ml, 5 μg/ml and 50 μg/ml. Phase contrast micrographs were taken 24 hours after treatment. (B) Proliferation assay. Cells 
were treated with medium containing 4% FCS and cilengitide at the concentrations indicated, trypsinized and counted after 24, 
48 and 72 hours incubation at 37°C. (C) Apoptosis. Floating and attached cells were collected 24 hours after treatment with 
cilengitide at the indicated concentrations. Apoptosis was assessed by flow cytometry after annexin V and propidium iodide 
staining. Experiments were performed in triplicate.
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of adherent growing cells (fig. 3C). When cilengitide was
added to non-adherent cells no increase in the rate of
apoptosis was observed (fig. 4). Therefore, the mechanism
of cilengitide-mediated apoptosis was indistinguishable
from anoikis, suggesting that the anti-adhesive effect of
cilengitide is responsible for apoptosis induction.
Cilengitide inhibits FAK, Src and VEGF-induced ERK1/2 
phosphorylation in endothelial cells
Cilengitide has been shown to inhibit proliferation and to
induce apoptosis in endothelial cells, but its effects on
integrin mediated signaling pathways are unknown.
Therefore we studied the effect of integrin blockade by
cilengitide on the phosphorylation and thus activation of
p38 MAPK, p44/42 MAPK (Erk1/2), FAK, Src and Akt.
After 24 h of starvation in serum-free medium HUVECs
grown on uncoated dishes were treated with 20, 40 and 60
μg/ml cilengitide for 1 hour and the activation of signal-
ing molecules was evaluated by Western blotting with
phosphoprotein-specific antibodies. As shown in figure
5A, integrin blockade moderately reduced phosphoryla-
tion of FAK and Src dose-dependently, but not of Erk 1/2
and p38 (data not shown) under this conditions. Densit-
ometric analyses were performed to quantify the effects
on signalling events (figure 5B).
Integrins can physically interact with growth factor recep-
tors to regulate a variety of biological processes. In partic-
ular, the interaction between αvβ3 integrin and KDR is
important for downstream signaling of both receptor
types [28,29]. Given that cilengitide interacts with the
extracellular domain of αvβ3, and might thereby interfere
with the association of KDR with αvβ3 integrin, we exam-
ined whether cilengitide also affects downstream compo-
nents of KDR signaling pathways. Stimulation of PAE-
KDR cells (porcine aortic endothelial cell line stably trans-
fected with VEGFR-2/KDR) with VEGF induced phospho-
rylation of KDR, FAK and Erk. Simultaneous treatment of
PAE-KDR cells with VEGF and cilengitide (1, 5 and 50 μg/
ml) did not alter KDR activation when comparing to total
KDR protein but inhibited phosphorylation of FAK (fig-
ure 5C/D). Erk phosphorylation was decreased only at
higher concentrations of cilengitide (50 μg/ml) after 10
minutes, which may be due to pathway crosstalk, since
KDR activity was not inhibited under these conditions.
These results suggest that cilengitide inhibits integrin-
Effects of cilengitide on cell adhesion and morphology of glioma cell lines G28 and G44 Figure 2
Effects of cilengitide on cell adhesion and morphology of glioma cell lines G28 and G44. Cell lines G28 (left panel) 
and G44 (right panel) were treated with full medium (A, B) or cilengitide at concentrations of 1 μg/ml (C, D), 5 μg/ml (E. F) and 
50 μg/ml (G, H) in full medium. Phase contrast micrographs were taken 24 hours after treatment.
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dependent signaling through FAK and Src while it does
not influence VEGFR-2/KDR and its downstream path-
ways in endothelial cells.
Cilengitide inhibits phosphorylation of FAK, Src and Akt in 
glioma cells
We next studied the effect of cilengitide on integrin-medi-
ated signaling pathways in the absence of VEGF in glioma
cells. In order to determine the optimal time frame for sig-
naling events G28 cells were lyzed after 30, 60 and 120
minutes of incubation with cilengitide (50 μg/ml) and
analyzed for activation of FAK and Akt by Western blot
using phospho-specific antibodies. As shown in figure 6A
and 6B, inhibition of FAK phosphorylation by cilengitide
was observed already at 30 minutes and this effect contin-
ued for at least until 1 hour. Additionally, inhibition of
pAkt was noted after 60 minutes. Therefore, following
experiments were performed with incubations of 1 hour
using increasing concentrations of cilengitide. Incubation
with cilengitide under these conditions caused inhibition
Cilengitide inhibits proliferation and induces apoptosis in glioma cell lines G28 and G44 Figure 3
Cilengitide inhibits proliferation and induces apoptosis in glioma cell lines G28 and G44. Proliferation assay. Cell 
lines G28 (A) and G44 (B) were treated with control medium or with medium containing cilengitide at the concentrations indi-
cated and then trypsinized and counted after 24, 48 and 72 hours incubation at 37°C. Apoptosis. Floating and attached G28 (C) 
and G44 (D) cells were collected 24 hours after treatment with cilengitide at the indicated concentrations. Apoptosis was 
assessed by flow cytometry after annexin V and propidium iodide staining.
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of Src and Akt phosphorylation downstream of FAK in a
dose dependent manner as shown in figure 6C. Results
were quantified using densitometric analyses (figure 6D).
These results demonstrate that cilengitide inhibit identical
pathways in glioma and endothelial cells explaining sim-
ilar effects such as detachment and apoptosis induction
observed in both cell types.
Cilengitide induces disassembly of tight junctions and actin 
cytoskeleton
To analyze the effect of cilengitide on the distribution of
the tight junction proteins and actin filaments, we per-
formed immunofluorescent staining of endothelial
(HMEC-1) and glioma cells (G28) for zona occludens
(ZO-1) and phalloidin.
In control cells staining with ZO-1 highlighted tight junc-
tions at cellular borders with continuous staining along
cell-cell contacts on both HMEC-1 and G28 cells (fig. 7A,
7C). Cells exposed to cilengitide for 24 hours lost distri-
bution of ZO-1 to intercellular junctions, showing irregu-
lar distribution with sporadic cytoplasmatic aggregates
(figures 7E, 7I, 7G, 7K).
PE-phalloidin staining of actin cytoskeleton, revealed a
disassembly of actin filaments in cilengitide treated
endothelial and glioma cells compared to controls (fig-
ures 7B, 7D). With the disappearance of the actin fibers
from the cell interior, we observed clustering of microfila-
ments along cell borders (figures 7F, 7J, 7H, 7L). Although
effects were similar in both cell types, glioma cells
appeared more sensitive for disassembly of filaments and
Cilengitide inhibits FAK and Src but not VEGF-induced phosphorylation of KDR and ERK1/2 in endothelial cells Figure 5
Cilengitide inhibits FAK and Src but not VEGF-induced phosphorylation of KDR and ERK1/2 in endothelial 
cells. (A) Western blotting and (B) densitometric analysis of FAK, Src and Erk1/2 in HUVEC. Cells were maintained 24 hours 
in serum-free medium on uncoated dishes and then treated with cilengitide for 1 hour at concentrations indicated. Cell lysates 
were separated by SDS-PAGE and transferred to a nitrocellulose membrane to detect phosphorylated FAK, Src and Erk1/2. 
(C) Western blotting analysis of FAK, KDR and Erk1/2 and (D) densitometric analysis of FAK and Erk1/2 in PAE-KDR cells. 
Cells were maintained 24 hours in serum-free medium, treated with VEGF (5 ng/ml) and cilengitide at concentrations indicated 
and incubated 30 minutes on ice and 7 minutes at 37°C. For detection of FAK and Erk1/2, cell lysates containing same amount 
of protein were separated by SDS-PAGE and transferred to a nitrocellulose membrane. For detection of KDR, cells were 
extracted and subjected to KDR immunoprecipitation. Total proteins from immunoprecipitates were separated by SDS-PAGE 
and transferred to a nitrocellulose membrane. Thereafter, membranes were probed with specific antibodies against phosphor-
ylated FAK, KDR and Erk1/2.
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cellular detachment. These observations highlight the
profound changes on intercellular contacts and cytoskele-
ton caused by cilengitide similarly in endothelial and gli-
oma cells.
MGMT promotor methylation status of glioma cell lines
Temozolomide (TMZ) is a DNA-methylating agent with
activity as monotherapy in malignant gliomas [30-32].
However the benefit from temozolomide treatment in
glioblastoma is strongly associated with MGMT promoter
methylation [33]. Therefore, we determined the MGMT
promotor methylation status using a methylation-specific
PCR assay. Cell lines G28 and 44 both had a methylated
MGMT promotor as shown in figure 8. Lymphocytes from
peripheral blood of healthy volunteer served as negative
controls with unmethylated promotor, while a positive
control was clearly methylated.
Effect of cilengitide and temozolomide on glioma cells
We next studied the effect of temozolomide (TMZ) in
combination with cilengitide on glioma cellls with meth-
ylated MGMT promotor. G28 and G44 cells were incu-
bated with cilengitide (5 μg/ml) and temozolomide (5 μg/
ml) alone or in combination for 72 hours and changes
were studied after 24, 48 and 72 hours. In contrast to cells
treated with cilengitide, where many cells detached
already after 24 hours (fig. 9C, 9D), G28 (left) and G44
(right) cells treated with TMZ alone did not show mor-
phological changes or cellular detachment when com-
pared to controls (fig. 9E, 9F). The combination of
cilengitide and TMZ led to an increased detachment of gli-
oma cells and cell cluster formation being more pro-
nounced after 48 hours (fig 9G, 9H).
Effect of cilengitide and temozolomide on proliferation 
and apoptosis of glioma cells
Glioma cell lines G28 and G44 were treated with 5 μg/ml
cilengitide and 5 μg/ml temozolomide alone or in combi-
nation and cell counts were determined after 24 and 48
hours. As expected, an inhibitory effect on cell prolifera-
tion was observed on glioma cells treated with cilengitide
already after 24 hours, whereas treatment with temozolo-
mide alone showed only slight inhibition of proliferation
in G44 and G28 glioma cells. When cilengitide was com-
bined with temozolomide proliferation inhibition was
slighty pronounced in both cell lines. Quantification of
proliferation inhibition by either cilengitide or TMZ alone
compared to the combination of both compounds sug-
Cilengitide inhibits phosphorylation of FAK, Src and Akt in glioma cells Figure 6
Cilengitide inhibits phosphorylation of FAK, Src and Akt in glioma cells. G28 cells were treated with 50 μg/ml cilen-
gitide for 30, 60 and 120 minutes at 37°C. Cell lysates containing similar amounts of protein were separated by SDS-PAGE, 
transferred to a nitrocellulose membrane and probed with specific antibodies for detection of β-actin and phosphorylated FAK 
and Akt (A). pFAK and pAkt were quantified by densitometry (OD/mm2) (B). G28 cells were treated with cilengitide at the 
concentrations indicated for 1 hour at 37°C. Cell lysates were separated by SDS-PAGE and transferred to a nitrocellulose 
membrane to detect β-actin and phosphorylated Src and Akt (C). pSrc and pAkt were then quantified by densitometry (OD/
mm2 (D).
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gested additive effects of cilengitide and TMZ in G44 cells
(fig. 10A). The combination caused additional inhibiton
in G28 cells. However the data are to limited to propose a
synergism of the combination in these cells (fig. 10B).
Differences observed between cell lines might be due to
higher integrin expression in G44 compared to G28 cells
(data not shown).
Annexin V/propidium iodide staining demonstrated sim-
ilar apoptosis induction after incubation with either cilen-
gitide or temozolomide in G44 cells. The combination of
both compounds further increased the amount of apop-
totic cells (fig. 10C). Apoptosis induction in G28 cells was
less pronounced, but showed similar trends (fig. 10D).
Taken together, these results suggest additive activity of
cilengitide combined with TMZ in glioma cells with meth-
ylated MGMT promotor.
Discussion
Experimental data indicated that integrin inhibition using
αvβ3 and αvβ5 antagonists may serve as an attractive
antiangiogenic therapeutic approach in tumor therapy
[34]. Antisense strategies [22], monoclonal antibodies
[35] and RGD-related molecules [36,37] have been devel-
oped in the previous years and are in various phases of
experimental and clinical development [38]. Cilengitide,
a polypeptide compound with inhibiting activity on both
αvβ3 and αvβ5 integrins has been tested in patients with
various advanced solid tumors [39] and profound activity
was reported from clinical trials in malignant gliomas
[20,21]. For the combination of cilengitide with TMZ the
MGMT promotor methylation status seemed to be predic-
tive for therapy response to the combination [21]. In the
trial using single agent cilengitide after TMZ failure data
regarding MGMT methylation status were not analyzed
[20].
Details of the molecular mechanisms of cilengitide in
endothelial and glioma cells have not been studied to our
knowledge. In our experiments, we observed dose
dependent cell rounding and detachment of endothelial
cells in tissue culture with cells undergoing apoptosis
upon loosing attachment. The morphological changes
were accompanied by the loss of intercellular contacts and
Cilengitide induces disassembly of tight junctions and actin cytoskeleton in endothelial and glioma cells Figure 7
Cilengitide induces disassembly of tight junctions and actin cytoskeleton in endothelial and glioma cells. HMEC-
1 (left panel) or G28 cells (right panel) were treated with full medium (A-D) or cilengitide at concentrations of 1 μg/ml (E-H) 
and 5 μg/ml (I-L) in full medium for 24 hours. Cells were then fixed and stained for ZO-1 (green) and actin (red).
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Methylation status of MGMT promotor in glioma cell 
lines G28 and G44. A methylation-specific PCR assay was 
used with universal methylated human DNA Standard as a 
positive control for methylation, peripheral blood lym-
phocytes (PBL) as a negative control for methylation and 
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disorganization of cellular cytoskeleton. Signaling experi-
ments revealed inhibition of integrin-dependent activa-
tion of FAK, Src and Akt in two endothelial cell lines,
HUVEC and PAE-KDR cells. Cilengitide did not notably
interact with KDR-phosphorylation or Erk activation
downstream of KDR, although direct interactions between
VEGF receptors and integrins have been reported earlier
[28,29]. Activity of MAPKinases p38, pJNK and pErk was
not altered by cilengitide in HUVEC cells (not shown).
Recently, similar changes have been reported for S 36578-
2, a novel RGD mimetic with selective activity on αvβ3
and αvβ5 integrins [40]. This compound induced detach-
ment and was shown to induce apoptosis by direct activa-
tion of caspase-8. Since this could be mimicked by culture
under non-adhering conditions, the authors stated that
anoikis, apoptosis occurring after disruption of cell-
matrix interaction, is the underlying mechanism of cell
death caused by integrin inhibition.
Earlier data suggested that cilengitide also induces detach-
ment of glioma cells from ECM structures, depending on
the matrix used [23]. Further evidence came from other
compounds such as contortrostatin, a snake venom disin-
tegrin also based on a RGD-polypeptide [41] and another
synthetic RGD-peptide [37] both inducing apoptosis of
integrin-expressing glioma cells. Using human glioma cell
lines expressing αvβ3 and αvβ5 integrins cilengitide
caused a profound detachment and increase of apoptosis
in glioma cells similar to what was seen in endothelial
cells suggesting that identical mechanisms might occur in
both cell types. Indeed, signaling through FAK, Src and
Akt was inhibited in the same fashion as observed in
endothelial cells.
Tumstatin a collagen IV cleavage product, which has been
described as antiangiogenic in vitro and  in vivo acts
through inhibition of αvβ3 integrin in endothelial cells
[42]. Interestingly, tumstatin was also shown to inhibit
growth of glioma cells. Similar to cilengitide its activity is
mediated through Akt [43]
Cilengitide induced proliferation inhibition and apopto-
sis induction in cell lines with methylated MGMT promo-
tor, a predictive factor for responsivness to alkylating
agents such as TMZ. TMZ alone was only slightly active in
these cells in the concentration used. The combination of
both agents did improve response in respect to prolifera-
Effects of cilengitide in combination with temozolomide on cell adhesion and morphology of glioma cells Figure 9
Effects of cilengitide in combination with temozolomide on cell adhesion and morphology of glioma cells. Cell 
lines G28 (left panel) and G44 (right panel) were treated for 24 hours with full medium containing DMSO (A, B), cilengitide at 
a concentration of 5 μg/ml (C, D), temozolomide (5 μg/ml) (E, F) or cilengitide combined with temozolomide, both at a con-
centration of 5 μg/ml (G, H) in full medium. Phase contrast micrographs were taken 72 hours after treatment. Results from a 
representative experiment (of at least 3) are shown.
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tion and apoptosis compared to cilengitide alone. These
results confirm, that cilengitide is active in glioma cells
with methylated MGMT promotor as shown in a clinical
trial investigating the combination of cilengitide and TMZ
[21]. Interestingly, synergistic effects of cilengitide and
TMZ have been recently shown for melanoma [44].
Conclusion
Our data demonstrate molecular and morphological
changes induced by cilengitide in integrin-expressing
endothelial and glioma cells leading to disruption of cel-
lular contacts and induction of apoptosis/anoikis.
Whether the in vivo effect of cilengitide is restricted to gli-
oma cells or both endothelial and tumor cells is not clear
yet and should be further investigated in order to under-
stand the activity of cilengitide in malignant glioma and
help to further improve treatment of this entity.
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